Table 1 Patients’ characteristics.
Characteristic | All patients (n = 577) |
|---|---|
Median patient age, year (range) | 40 (6–71) |
Median donor age, year (range) | 32 (8–69) |
Patient sex | |
Male | 346 (60.0%) |
Female | 231 (40.0%) |
Donor sex | |
Male | 386 (66.9%) |
Female | 191 (33.1%) |
Patient–donor sex | |
Female to male | 104 (18.0%) |
Others | 473 (82.0%) |
GVHD prophylaxis | |
ATG + CSA + MTX + MPA | 170 (29.5%) |
ATG + CSA + CTX + MPA | 340 (58.9%) |
CTX + CSA + MPA | 67 (11.6%) |
Conditioning regimens | |
MAC | 439 (76.1%) |
RIC | 138 (23.9%) |
Diagnosis | |
AML | 298 (51.6%) |
ALL | 104 (18.0%) |
MDS | 102 (17.7%) |
NHL | 73 (12.7%) |
Risk stratification | |
Low risk | 107 (18.5%) |
Intermediate risk | 152 (26.3%) |
High risk | 318 (55.1%) |
Disease status | |
CR | 445 (77.1%) |
NR | 132 (22.9%) |
ECOG | |
0 | 392 (67.9%) |
1 | 162 (28.1%) |
2 | 15 (2.6%) |
3–4 | 8 (1.4%) |
HCT-CI | |
<3 | 550 (95.3%) |
≥3 | 27 (4.7%) |
Median CD34+ cell (×106/kg), range | 11.12 (1.58–46.55) |
Median CD3 + T cell (×108/kg), range | 3.30 (0.61–10.8) |
